Kadmon Holdings (KDMN) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Kadmon Holdings (KDMNResearch Report) today and set a price target of $13.00. The company’s shares closed last Wednesday at $4.60.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 12.4% and a 38.8% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kadmon Holdings with a $10.20 average price target, representing a 130.2% upside. In a report issued on July 26, Jefferies also assigned a Buy rating to the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

Kadmon Holdings’ market cap is currently $777.3M and has a P/E ratio of -6.50. The company has a Price to Book ratio of 70.42.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.